cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Kymera Therapeutics Inc
3 own
3 watching
Current Price
$35.09
$1.33
(3.94%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,292.36M
52-Week High
52-Week High
45.31000
52-Week Low
52-Week Low
9.60000
Average Volume
Average Volume
0.25M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization1,292.36M
icon52-Week High45.31000
icon52-Week Low9.60000
iconAverage Volume0.25M
iconDividend Yield--
iconP/E Ratio--
What does the Kymera Therapeutics Inc do?
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body s own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Read More
How much money does Kymera Therapeutics Inc make?
News & Events about Kymera Therapeutics Inc.
Stock Options Channel
9 months ago
Investors considering a purchase of Kymera Therapeutics Inc (KYMR) shares, but cautious about paying the going market price of 22.35/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the December...
Globe Newswire
10 months ago
WATERTOWN, Mass., June 22, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the U.S. Food and Drug Administration (FDA...
Globe Newswire
10 months ago
Data shared today on PK/PD and safety from additional KT-333 and KT-413 patient dose escalation cohorts show target knockdown at or near levels associated with clinical efficacy in preclinical tumor models No dose limiting toxicities observed in either program KT-333 data will be presented in a ...
Globe Newswire
10 months ago
A single dose of KT-253 drives tumor regression and demonstrates differentiated pharmacology compared to small molecule inhibitor (SMI) in preclinical models of ALL and AMLWATERTOWN, Mass., June 09, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical...
Market News Video
11 months ago
In trading on Thursday, shares of Kymera Therapeutics Inc (KYMR) crossed below their 200 day moving average of 29.07, changing hands as low as 26.43 per share. Kymera Therapeutics Inc shares are currently trading down about 13.4% on the day...
Frequently Asked Questions
Frequently Asked Questions
What is Kymera Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Kymera Therapeutics Inc shares?
plus_minus_icon
How can I buy Kymera Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Kymera Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Kymera Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Kymera Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Kymera Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Kymera Therapeutics Inc?
plus_minus_icon
What percentage is Kymera Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Kymera Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$35.09
$1.33
(3.94%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
ZENTALIS PHARMACEUTICALS INC
ZENTALIS PHARMACEUTICALS INC
$12.54
$-0.17 (-1.34 %)
TARSUS PHARMACEUTICALS INC
TARSUS PHARMACEUTICALS INC
$32.85
$-1.57 (-4.56 %)
PMV PHARMACEUTICALS INC
PMV PHARMACEUTICALS INC
$1.63
$0.02 (1.24 %)
KEROS THERAPEUTICS INC
KEROS THERAPEUTICS INC
$59.08
$-0.19 (-0.32 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
ZENTALIS PHARMACEUTICALS INC
ZENTALIS PHARMACEUTICALS INC
$12.54
$-0.17 (-1.34 %)
TARSUS PHARMACEUTICALS INC
TARSUS PHARMACEUTICALS INC
$32.85
$-1.57 (-4.56 %)
PMV PHARMACEUTICALS INC
PMV PHARMACEUTICALS INC
$1.63
$0.02 (1.24 %)
KEROS THERAPEUTICS INC
KEROS THERAPEUTICS INC
$59.08
$-0.19 (-0.32 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Foreside Fund Services acts as the distributor to the DriveWealth ICE 100 Index ETF and is not affiliated with Borderless Investing Inc, DriveWealth LLC, BlackOak Investors LP, ACR Group, or other entities referenced on this website.

              Get Started with as little as $1.00